Haemonetics Corporation (NYSE:HAE) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Haemonetics Corporation (NYSE:HAE) have been given an average recommendation of “Moderate Buy” by the eleven brokerages that are covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $84.4444.

Several equities research analysts recently issued reports on HAE shares. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a research note on Monday, December 29th. Raymond James Financial reissued an “outperform” rating and set a $90.00 price objective on shares of Haemonetics in a research note on Friday, November 14th. Mizuho dropped their price objective on Haemonetics from $90.00 to $80.00 and set an “outperform” rating for the company in a report on Friday, February 6th. Finally, Citigroup cut their target price on Haemonetics from $88.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th.

Hedge Funds Weigh In On Haemonetics

Hedge funds and other institutional investors have recently modified their holdings of the company. Kemnay Advisory Services Inc. acquired a new position in shares of Haemonetics during the fourth quarter worth $26,000. True Wealth Design LLC increased its stake in Haemonetics by 6,700.0% during the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 335 shares during the period. Leonteq Securities AG acquired a new position in Haemonetics in the 4th quarter worth $30,000. EverSource Wealth Advisors LLC lifted its holdings in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 396 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in Haemonetics in the 4th quarter valued at about $34,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Price Performance

Shares of NYSE:HAE opened at $60.56 on Thursday. The company has a market cap of $2.81 billion, a P/E ratio of 16.68, a P/E/G ratio of 1.23 and a beta of 0.28. The business has a fifty day simple moving average of $72.87 and a 200-day simple moving average of $64.18. Haemonetics has a 52 week low of $47.31 and a 52 week high of $87.32. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. The firm had revenue of $338.97 million for the quarter, compared to analyst estimates of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The firm’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period last year, the company earned $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Equities research analysts forecast that Haemonetics will post 4.55 EPS for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.